🇺🇸 FDA
Patent

US 10335391

Stabilized oxymetazoline formulations and their uses

granted A61KA61K31/4164A61K31/4174

Quick answer

US patent 10335391 (Stabilized oxymetazoline formulations and their uses) held by Aclaris Therapeutics, Inc. expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aclaris Therapeutics, Inc.
Grant date
Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K31/4164, A61K31/4174, A61K47/10, A61K47/12